Final Stretch for the Fertility Focus Campaign

Further Institutional Investor Backing for the company behind OvuSense

The campaign for Fertility Focus has entered its final stretch on the Shadow Foundr platform and will be concluding in August on the back of further positive news.

Fertility Focus, the fertility technology experts behind OvuSense, a revolutionary, patented product which doubles the chances of conception each month, has just confirmed an additional £949k of funding from a leading institutional investor and group of high net worths. On the back of record sales and highest ever revenues in the first half of 2018, it is another significant boost for Fertility Focus.

Added to the £154k raised to date in this round it means Fertility Focus is well placed as it heads into the final few days of its funding round with Shadow Foundr. It is now seeking the final £500,000 worth of investment to complete the raise in this round on a first come first served basis at a pre-money valuation of £4.6m.

The potential target market for OvuSense is significant, with 12 million new women entering the pool of those trying to conceive every year. Clinical studies show that four million of that pool struggle for six months or more to conceive, and that 70% suffer from ovulatory issues which cause disruption in the timing of ovulation. OvuSense is uniquely placed to help those women because it can predict ovulation in real time using data from the current cycle which is not disrupted by those ovulatory issues.

If you want to invest in a business that is delivering a high margin SaaS revenue stream, which has serious institutional backing, is EIS eligible, and is transforming the lives of women and their families across the globe, or to learn more, please click here.

Become a member – follow the lead of experienced investors. Sign Up